Chemomab Publishes Phase 2 SPRING Trial Results for PSC Treatment
Chemomab Therapeutics announced that the results of its Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis, PSC, were published in the current issue of the American Journal of Gastroenterology. The study showed that nebokitug was generally safe and well tolerated in patients with PSC for up to 48 weeks of treatment. Patients treated with nebokitug had numerical improvements in a range of biomarkers for inflammation and fibrosis, particularly at the 20 mg/kg dose and in the pre-specified subgroup of patients with moderate/advanced fibrosis. The authors conclude that these promising data support further evaluation of nebokitug for the treatment of PSC in a Phase 3 clinical trial.
Trade with 70% Backtested Accuracy
Analyst Views on CMMB
About CMMB
About the author
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
Chemomab Therapeutics Reports Q1 Financial Results
- Financial Performance: Chemomab Therapeutics reported a GAAP EPS of $0.00 for Q1 2026, with a net loss of $1.8 million, an improvement from a net loss of $3.3 million in Q1 2025, indicating efforts in cost control.
- Per Share Loss: The net loss per basic and diluted ordinary share for Q1 2026 remained below $0.01, reflecting stable financial performance despite ongoing losses, which may impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $8.0 million in cash, cash equivalents, and short-term bank deposits, down from $10.4 million as of December 31, 2025, highlighting challenges in cash management.
- Funding Outlook: The current cash runway is expected to sustain operations through the end of Q1 2027, indicating a need for careful financial planning to ensure continued operational viability.
Chemomab Therapeutics Reports Q4 Financial Results
- Net Loss Overview: Chemomab Therapeutics reported a net loss of $1.9 million for Q4, translating to less than $0.01 per share, indicating financial strain under ongoing R&D investments that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company held $10.4 million in cash, cash equivalents, and short-term bank deposits, which, while providing some liquidity, necessitates careful management to support ongoing operations and research.
- Financial Transparency: Chemomab Therapeutics has provided detailed financial information, reflecting its commitment to transparency, which could help bolster investor confidence despite the current poor financial performance.
- Market Reaction Outlook: Given the ongoing net losses and limited cash reserves, the market is expected to maintain a cautious stance towards Chemomab's future performance, potentially affecting its stock price and investor sentiment.
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
Chemomab Therapeutics Reports Q1 Financial Results
- Financial Performance: Chemomab Therapeutics reported a GAAP EPS of $0.00 for Q1 2026, with a net loss of $1.8 million, an improvement from a net loss of $3.3 million in Q1 2025, indicating efforts in cost control.
- Per Share Loss: The net loss per basic and diluted ordinary share for Q1 2026 remained below $0.01, reflecting stable financial performance despite ongoing losses, which may impact investor confidence.
- Cash Position: As of March 31, 2026, the company had $8.0 million in cash, cash equivalents, and short-term bank deposits, down from $10.4 million as of December 31, 2025, highlighting challenges in cash management.
- Funding Outlook: The current cash runway is expected to sustain operations through the end of Q1 2027, indicating a need for careful financial planning to ensure continued operational viability.
Chemomab Therapeutics Reports Q4 Financial Results
- Net Loss Overview: Chemomab Therapeutics reported a net loss of $1.9 million for Q4, translating to less than $0.01 per share, indicating financial strain under ongoing R&D investments that may impact future funding capabilities.
- Cash Position: As of December 31, 2025, the company held $10.4 million in cash, cash equivalents, and short-term bank deposits, which, while providing some liquidity, necessitates careful management to support ongoing operations and research.
- Financial Transparency: Chemomab Therapeutics has provided detailed financial information, reflecting its commitment to transparency, which could help bolster investor confidence despite the current poor financial performance.
- Market Reaction Outlook: Given the ongoing net losses and limited cash reserves, the market is expected to maintain a cautious stance towards Chemomab's future performance, potentially affecting its stock price and investor sentiment.
Market Update: Tilray Drives After-Hours Gains as Biotech Stocks Soar
Tilray Brands Surge: Tilray Brands, Inc. saw an 11.36% increase in after-hours trading, reaching $13.53, following a one-for-ten reverse stock split and positive investor sentiment regarding its restructuring and beverage portfolio.
Valneva's Positive Trial Results: Valneva SE's stock rose by 7.22% after hours to $9.31, buoyed by favorable final data from its Phase 2 chikungunya vaccine trial, which supports future Phase 3 development plans.
Chemomab and Genenta Recovery: Chemomab Therapeutics Ltd. gained 7.66% after hours to $2.39, while Genenta Science S.p.A. climbed 12.06% to $1.58, both recovering from earlier declines and reacting to recent clinical trial updates.
Kazia and Traws Pharma Movements: Kazia Therapeutics Limited increased by 10.93% after hours to $11.57, following a presentation on its cancer treatment, while Traws Pharma, despite no new developments, edged up 8.81% to $2.54, driven by low-float trading momentum.
Top Strong Buy Stocks for October 23: MQ, GES, and Others
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including Marqeta, Guess?, The Travelers Companies, Chemomab Therapeutics, and Par Pacific Holdings, with significant increases in their earnings estimates over the past 60 days.
Quantum Computing Revolution: Quantum computing is rapidly advancing and is seen as the next major technological revolution, with major companies like Microsoft, Google, and Amazon integrating it into their infrastructure.
Investment Opportunities: Senior Stock Strategist Kevin Cook has identified seven stocks that are expected to lead in the quantum computing sector, suggesting a potential investment opportunity for those looking to capitalize on this emerging technology.
Free Stock Analysis Reports: The article offers free stock analysis reports for the highlighted companies, providing additional insights for investors interested in these stocks.
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Ventyx Biosciences Surge: Ventyx Biosciences' shares skyrocketed over 88% after positive Phase 2 trial results for its obesity and cardiovascular risk treatment, VTX3232.
Medpace Holdings Performance: Medpace Holdings saw an 18% increase in shares following better-than-expected Q3 results and an updated fiscal year 2025 guidance.
Inhibrx Biosciences Update: Inhibrx Biosciences' shares rose over 10% as the company announced a live webcast to present topline results from its ChonDRAgon study on ozekibart for chondrosarcoma.
Other Notable Movers: Several biotech stocks, including Acumen Pharmaceuticals and SCYNEXIS, experienced significant after-hours gains, reflecting a broader positive trend in the sector.
